Medical News

RSS

Baptist Healthcare System deploys Mckesson's Horizon Enterprise Revenue Management solution

Kentucky-based Baptist Healthcare System plans to stay ahead of the information technology curve. When a switch was flipped on Aug. 15 at Baptist Hospital Northeast in La Grange, Ky., the health system became the first to simultaneously implement both the access and business management modules of McKesson’s Horizon Enterprise Revenue Management™ solution.

5 Oct 2009

Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

CombinatoRx, Incorporated, today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A CombinatoRx-derived combination drug candidate, Prednisporin, (FOV1101), which is a fixed dose combination of prednisolone and cyclosporine, is the most advanced product asset in the Fovea pipeline, with Phase 2b clinical studies planned for the treatment of persistent allergic conjunctivitis.

5 Oct 2009

Coventry Health Care signs definitive agreement to acquire Preferred Health Systems

Coventry Health Care, Inc. (NYSE: CVH) announced today that it has signed a definitive agreement to acquire Preferred Health Systems, Inc. (“PHS”), a wholly-owned subsidiary of Via Christi Health System, Inc.

5 Oct 2009

QuadraMed announces the launch of its ICD-10 Countdown Program

QuadraMed® Corporation, a leading provider of healthcare information technologies and services that help turn quality care into positive financial outcomes, today announced the launch of its ICD-10 Countdown Program. This new program includes the Quantim® ICD-10 Coding Simulator software, ICD-10 educational tools and services to guide healthcare providers through the ICD-10 conversion.

5 Oct 2009

Biochemics signs research collaboration agreement with Unilever

BioChemics, Inc. a company “enhancing drug delivery through biophysical modulation,” is pleased to announce the signing of a research collaboration agreement with Unilever, one of the world’s largest consumer goods companies, to utilize BioChemics’ proprietary topical delivery technology for the delivery of Unilever’s compounds.

5 Oct 2009

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations.

5 Oct 2009

SonoSite Mobile Solutions for cordless charging of ultrasound systems

SonoSite, Inc., the world leader and specialist in hand-carried and point-of-care ultrasound, announced today SonoSite® Mobile Solutions, for cordless charging and extended battery life of its ultrasound systems.

5 Oct 2009

SonoSite launches Workflow Solutions for streamlining exam management of ultrasound studies

SonoSite, Inc., the world leader and specialist in hand-carried and point-of-care ultrasound, announced today the introduction of SonoSite® Workflow Solutions (SWS™), a suite of specialized tools designed to streamline exam management at the departmental level by giving physicians the ability to browse, manage and store ultrasound studies and generate reports suitable for billing and credentialing.

5 Oct 2009

Rxi Pharmaceuticals to ring Nasdaq closing bell in NYC's Times Square

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that Tod Woolf, Ph.D., President and CEO, along with members of RXi’s management team, will ring the Nasdaq closing bell tomorrow, Tuesday, Oct 6, 2009 at the Nasdaq Marketsite in New York City’s Times Square.

5 Oct 2009

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

Today, at the American Academy of Otolaryngology-Head and Neck Surgery annual meeting, ImThera Medical, Inc. unveiled its new product, the aura6000™ neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA).

5 Oct 2009

New technique for tracing ultra-fine particles

Limit values for fine dust emissions are based on total particle weight. It is the ultra-fine particles, however, that are particularly harmful to health. A new technique separates them by size and identifies their composition - directly where they arise.

5 Oct 2009

Jefferies expands its global Healthcare Investment Banking Group

Jefferies today announced the expansion of its global Healthcare Investment Banking Group with the hiring of five senior professionals. Henry Elphick, Tommy Erdei and Probir Rao join as Managing Directors, Gil Bar-Nahum as a Senior Vice President, and Andrew Clayton as a Vice President. Henry Elphick, Tommy Erdei and Gil Bar-Nahum are based in London, Probir Rao is based in Mumbai, and Andrew Clayton in Hong Kong.

5 Oct 2009

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.

5 Oct 2009

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Theraclone Sciences, Inc., a Seattle-based biotechnology company, and Zenyaku Kogyo Co., Ltd., a pharmaceutical company based in Tokyo, today announced that they have entered into a multi-year research and development agreement.

5 Oct 2009

NCCNHR launches major strategic planning process for individuals receiving long-term care

NCCNHR (formerly the National Citizens' Coalition for Nursing Home Reform) announced today the launch of a major strategic planning process which will help strengthen the organization's role as a voice for individuals receiving long-term care.

5 Oct 2009

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin’s proprietary technology.

5 Oct 2009

First edition: October 5, 2009

The continuing efforts to make progress on the nation's health overhaul are reflected in today's headlines, which highlight both politics and policies.

5 Oct 2009

NanoViricides completes a number of financing activities

NanoViricides, Inc. (the "Company"), announced today that it has completed a number of financing activities.

5 Oct 2009

Medical News

Baptist Healthcare System deploys Mckesson's Horizon Enterprise Revenue Management solution

Prednisporin is a key asset in the proposed acquisition of Fovea by Sanofi-Aventis

Coventry Health Care signs definitive agreement to acquire Preferred Health Systems

QuadraMed announces the launch of its ICD-10 Countdown Program

Biochemics signs research collaboration agreement with Unilever

Pharmacogenomics Centre deploys the Isilon IQ to accelerate its next-generation genetic sequencing operations

SonoSite Mobile Solutions for cordless charging of ultrasound systems

SonoSite launches Workflow Solutions for streamlining exam management of ultrasound studies

Rxi Pharmaceuticals to ring Nasdaq closing bell in NYC's Times Square

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

New technique for tracing ultra-fine particles

Jefferies expands its global Healthcare Investment Banking Group

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

NCCNHR launches major strategic planning process for individuals receiving long-term care

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

First edition: October 5, 2009

NanoViricides completes a number of financing activities

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News